Abstract
Objective Acute coronary syndrome (ACS) incidence and case fatality (CF) have declined in the past decades, but some studies have suggested a potential stagnation in this decline. We examined how the ACS burden has evolved among persons aged 35-74 in Finland from 1996 to 2021.
Methods We used Finnish country-wide Hospital Discharge- and Causes of Death-Registers covering first non-fatal and fatal ACS events, totaling 69 906 442 person-years at risk. We analyzed incidence, mortality, and 28-day CF, and their trends using negative binomial, Poisson, segmented, and logistic regression adjusting for age and sex.
Results Altogether, the analysis consisted of 186 489 non-fatal and 72 907 fatal ACS events. ACS incidence declined in men (annual percentage change (APC) −2.0% [95% CI −2.2 to −1.8]) and in older women (APC of 55-64 year old −1.5% [−1.7 to −1.2] and 65-74 year old −3.3% [−3.4 to −3.2]), but the incidence decline slowed down over the last decade. In younger women aged 35-54, incidence was unchanged during the study period. ACS mortality and CF declined (APC of the mortality in men - 4.4% [−4.6 to −4.2] and in women −5.0% [−5.2 to −4.7]. APC of CF in men −2.7% [−2.8 to −2.6] and in women −3.3% [−3.6 to −3.1]).
Conclusions ACS mortality declined in all groups, but the decline in ACS incidence slowed down and even halted in women. In women aged 35-54, the incidence was unchanged during the study period. These results emphasize the need of intensified cardiovascular prevention, particularly in women.
What is already known on this topic During the last decades coronary artery disease treatment and prevention have improved worldwide which has led to a decline in ACS mortality and case fatality. However, recent studies from several countries suggest, that incidence decline has stagnated or even turned to increase, especially in younger age cohorts.
What this study adds This study showed that incidence has ceased its decline in women aged 35-54 and has slowed down in older age groups. Together with declining mortality this results in a growing number of patients living with cardiovascular disease leading to increased healthcare costs.
How this study might affect research, practice, or policy The alarming results of this study underline the importance of intensifying prevention, focusing especially on young and middle-aged women.
Competing Interest Statement
V.S. has had a research collaboration with Bayer Ltd (outside the present study).
Funding Statement
M.R. received support from Sigrid Juselius Foundation, Emil Aaltonen Foundation, Biomedicum Helsinki Foundation, Orion Research Foundation, and from Finnish Foundation for Cardiovascular Research. V.S. was supported by the Juho Vainio Foundation. I.H. was supported by Aarne Koskelo Foundation and Otto A. Malm Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Finnish Institute of Health and Welfare waived ethical approval for this work. For the use of Finnish Cardiovascular Disease Register (CVDR) data, the information permit number for the Finnish Cardiovascular Disease Register (CVDR) is THL/3624/6.02.00/2023.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All code produced in the present study are available upon reasonable request to the authors. Permission to access the original data can be applied for through FINDATA.
